Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancer
Kilian B. Kennel, … , Martin Schneider, Jonathan M. Harnoss
Kilian B. Kennel, … , Martin Schneider, Jonathan M. Harnoss
Published November 22, 2022
Citation Information: JCI Insight. 2022;7(22):e153337. https://doi.org/10.1172/jci.insight.153337.
View: Text | PDF
Research Article Inflammation Oncology

The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancer

  • Text
  • PDF
Abstract

Colitis-associated colorectal cancer (CAC) is a severe complication of inflammatory bowel disease (IBD). HIF-prolyl hydroxylases (PHD1, PHD2, and PHD3) control cellular adaptation to hypoxia and are considered promising therapeutic targets in IBD. However, their relevance in the pathogenesis of CAC remains elusive. We induced CAC in Phd1–/–, Phd2+/–, Phd3–/–, and WT mice with azoxymethane (AOM) and dextran sodium sulfate (DSS). Phd1–/– mice were protected against chronic colitis and displayed diminished CAC growth compared with WT mice. In Phd3–/– mice, colitis activity and CAC growth remained unaltered. In Phd2+/– mice, colitis activity was unaffected, but CAC growth was aggravated. Mechanistically, Phd2 deficiency (i) increased the number of tumor-associated macrophages in AOM/DSS-induced tumors, (ii) promoted the expression of EGFR ligand epiregulin in macrophages, and (iii) augmented the signal transducer and activator of transcription 3 and extracellular signal–regulated kinase 1/2 signaling, which at least in part contributed to aggravated tumor cell proliferation in colitis-associated tumors. Consistently, Phd2 deficiency in hematopoietic (Vav:Cre-Phd2fl/fl) but not in intestinal epithelial cells (Villin:Cre-Phd2fl/fl) increased CAC growth. In conclusion, the 3 different PHD isoenzymes have distinct and nonredundant effects, promoting (PHD1), diminishing (PHD2), or neutral (PHD3), on CAC growth.

Authors

Kilian B. Kennel, Julius Burmeister, Praveen Radhakrishnan, Nathalia A. Giese, Thomas Giese, Martin Salfenmoser, Jasper M. Gebhardt, Moritz J. Strowitzki, Cormac T. Taylor, Ben Wielockx, Martin Schneider, Jonathan M. Harnoss

×

Figure 7

The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancer.

Options: View larger image (or click on image) Download as PowerPoint
The HIF-prolyl hydroxylases have distinct and nonredundant roles in coli...
PHD1–3 have distinct effects on CAC growth, which is tumor promoting (PHD1), tumor inhibiting (PHD2), or neutral (PHD3). Intestinal inflammation is diminished in Phd1-deficient but unaltered in Phd2- and Phd3-deficient mice. In CAC, PHD2 deficiency (i) increases the number of TAMs, (ii) promotes Ereg expression in macrophages, and (iii) augments STAT3 and ERK1/2 signaling, which at least in part contributes to aggravated tumor cell proliferation in colitis-associated tumors.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts